HIF1A and neoplasm: Xu et al. [59] developed two novel Pt(IV) anticancer prodrugs, YCC-1 (Figure 8(13)) and YCC-2 (Figure 8(4)), which not only enhanced the platination of DNA but also inhibited the expression of HIF-1α via release of HIF-1α inhibitors from YCC-1 and, especially, from YCC-2 under hypoxia but not normoxia, thus significantly enhancing the sensitivity of tumor cells to cisplatin.